Our results further support that BRAF, already used as a putative predictive marker of the effectiveness of MAPK pathway inhibition therapy (www.clinicaltrials.gov), might also be useful, in skin melanomas, as a predictive marker of mTOR pathway inhibition therapy alone or in combination with MAPK inhibitors. This evidence concerns the gene MTOR and cutaneous melanoma.